iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
166.86
+4.51 (2.78%)
Aug 13, 2025, 4:00 PM - Market closed
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $186.69M in the quarter ending June 30, 2025, with 26.10% growth. This brings the company's revenue in the last twelve months to $657.23M, up 22.37% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$657.23M
Revenue Growth
+22.37%
P/S Ratio
8.01
Revenue / Employee
$328,614
Employees
2,000
Market Cap
5.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IRTC News
- 13 days ago - iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - iRhythm Technologies Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 19 days ago - IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC - Business Wire
- 27 days ago - iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewsWire
- 4 weeks ago - IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC - PRNewsWire
- 5 weeks ago - iRhythm Technologies Announces Board Member Retirements and New Director Appointments - GlobeNewsWire
- 7 weeks ago - New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Stockholders to Inquire about Securities Investigation - Accesswire